Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in the Ewing 2008R1 trial
CONCLUSION: In patients with standard-risk localized EWS, there is no additional benefit from maintenance treatment with ZOL.PMID:37843857 | DOI:10.1158/1078-0432.CCR-23-1966
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Raphael Koch Lianne Haveman Ruth Ladenstein B énédicte Brichard Heribert Juergens So ňa Cyprová Henk van den Berg Wolf Hassenpflug Anna Raciborska Torben Ek Daniel Baumhoer Gerlinde Egerer Leo Kager Marleen Renard Peter Hauser Stefan Burdach Judith V Source Type: research
More News: Bone Cancers | Brain | Cancer | Cancer & Oncology | Chemotherapy | Ewing's Sarcoma | Gastroenterology | Neurology | Reclast | Sarcomas | Toxicology | Zometa